Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 11, 2012, Pages 1125-1132

  Subramanian, Deepak R ^a   Jenkins, Lee ^b   Edgar, Ross ^b   Quraishi, Nabil ^a   Stockley, Robert A ^b   Parr, David G ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

1 antitrypsin deficiency; Computed tomography; Fluorodeoxyglucose F18; Neutrophil

Indexed keywords

ALPHA 1 ANTITRYPSIN; BECLOMETASONE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DENSITOMETRY; DISEASE EXACERBATION; DRUG UPTAKE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLYCOLYSIS; HUMAN; LUNG EMPHYSEMA; MALE; OPEN STUDY; PHENOTYPE; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULMONARY NEUTROPHILIC INFLAMMATION; QUANTITATIVE ANALYSIS; RADIOACTIVITY;

AGED; ALPHA 1-ANTITRYPSIN DEFICIENCY; BRONCHITIS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; FORCED EXPIRATORY VOLUME; GREAT BRITAIN; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84870454294     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201201-0051OC     Document Type: Article

References (43)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412.
2. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151S-155S.
3. Fujita J, Nelson NL, Daughton DM, Dobry CA, Spurzem JR, Irino S, Rennard SI. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir Dis 1990;142:57-62.
4. Ilumets H, Rytila PH, Sovijarvi AR, Tervahartiala T, Myllarniemi M, Sorsa TA, Kinnula VL. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scand J Clin Lab Invest 2008;68:618-623.
5. Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, Fallahnejad M, Weinbaum G. Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 1986;78:482-493.
6. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000;15:886-890.
7. Morrison HM, Kramps JA, Burnett D, Stockley RA. Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci (Lond) 1987;72:373-381.
8. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, Turino GM. Desmosine as a biomarker of elastin degradation in COPD: Current status and future directions. Eur Respir J 2008;32:1146-1157.
9. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007;62:595-601.
10. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, O'Connor GT, Benjamin EJ. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008;133:19-25.
11. Turino GM. COPD and biomarkers: the search goes on. Thorax 2008;63:1032-1034.
12. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
13. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14.
14. Jones HA, Boobis AR, Hamacher K, Coenen HH, Clark JC. PET imaging of pulmonary fibrosis. J Nucl Med 2003;44:483-484, author reply 484.
15. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, Hughes JM. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994;21:297-305.
16. Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, Kayani I, Menezes LJ, Dickson JC, Ell PJ. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009;50:538-545.
17. Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003;21:567-573.
18. Jones HA, Sriskandan S, Peters AM, Pride NB, Krausz T, Boobis AR, Haslett C. Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Respir J 1997;10:795-803.
19. Labiris NR, Nahmias C, Freitag AP, Thompson ML, Dolovich MB. Uptake of 18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation? Eur Respir J 2003;21:848-854.
20. Chen DL, Ferkol TW, Mintun MA, Pittman JE, Rosenbluth DB, Schuster DP. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med 2006;173:1363-1369.
21. Subramanian D, Jenkins L, Edgar R, Stockley R, Parr D. The evaluation and control of lung inflammation assessed with PET scanning in emphysema - alpha-1 antitrypsin deficiency (ECLIPSE-AATD) trial. Am J Respir Crit Care Med 2011;183:A6152.
22. Quanjer PH, Tammeling GJ, Cotes JE, Fabbri LM, Matthys H, Pedersen OF, Peslin R, Roca J, Sterk PJ, Ulmer WT, et al. Symbols, abbreviations and units. Working party standardization of lung function tests, European Community for Steel and Coal. Eur Respir J Suppl 1993;16:85-100.
23. Patlak CS. The effect of the previous generation on the distribution of gene frequencies in populations. Proc Natl Acad Sci USA 1953;39:1063-1068.
24. Bakker ME, Putter H, Stolk J, Shaker SB, Piitulainen E, Russi EW, Stoel BC. Assessment of regional progression of pulmonary emphysema with CT densitometry. Chest 2008;134:931-937.
25. Jones HA, Choudhury M, Harris DN. In vivo measurement of circulating leucocyte activation in patients following cardiopulmonary bypass. Nucl Med Biol 2004;31:965-969.
26. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
27. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63:1046-1051.
28. Chen DL, Azulay D-O, Atkinson JJ, Yusen RJ, Brody SL, Kozlowski J, Thomas BT, McCarthy TJ, Danto SI, Miller JP, et al. Reproducibility of positron emission tomography (PET)-measured [18F]Fluorodeoxyglucose ([18F]FDG) uptake as a marker of lung inflammation in chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2011;183:A6449.
29. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009;34:475-488.
30. Currie DC, Pavia D, Agnew JE, Lopez-Vidriero MT, Diamond PD, Cole PJ, Clarke SW. Impaired tracheobronchial clearance in bronchiectasis. Thorax 1987;42:126-130.
31. Jones HA, Cadwallader KA, White JF, Uddin M, Peters AM, Chilvers ER. Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of (18)F-FDG PET images. J Nucl Med 2002;43:652-657.
32. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008;12:361-367.
33. Woolhouse IS, Bayley DL, Lalor P, Adams DH, Stockley RA. Endothelial interactions of neutrophils under flow in chronic obstructive pulmonary disease. Eur Respir J 2005;25:612-617.
34. Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, Agusti AG. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432-437.
35. Sapey E, Stockley JA, Greenwood H, Ahmad A, Bayley D, Lord JM, Insall RH, Stockley RA. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1176-1186.
36. Paik JY, Ko BH, Choe YS, Choi Y, Lee KH, Kim BT. PMA-enhanced neutrophil [18F]FDG uptake is independent of integrin occupancy but requires PI3K activity. Nucl Med Biol 2005;32:561-566.
37. Burnett D, Chamba A, Hill SL, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987;2:1043-1046.
38. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1664-1668.
39. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
40. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004;170:492-498.
41. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-1455.
42. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung 2008;186:403-409.
43. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010;65:930-936.